Arca
Skip to content
Tools
Tools

ADORA2B: Adenosine receptor A2b

Receptor for adenosine.

  • Drugs that act on it: 4
  • Approved: 0
  • In phases 1 to 3: 4
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ADORA2B, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 3
  • Other 1

Approved0

    Phase 30

      Phase 21

      • Etrumadenant

      Phase 13

      • GS 6201
      • LAS101057
      • QAF805

      Sponsors

      Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Adenosine A2b receptor antagonist.
      EtrumadenantPhase 2Gilead SciencesSmall moleculeAntagonist8
      GS 6201Phase 1—Small moleculeAntagonist0
      LAS101057Phase 1—Small moleculeAntagonist0
      QAF805Phase 1—OtherAntagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      Combination Therapy in Patients With Localized Pancreatic Ductal AdenocarcinomaEtrumadenantPhase 2RecruitingGulam ManjiSep 21, 2023
      Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate CancerEtrumadenantPhase 2RecruitingCatherine SpinaJun 23, 2023
      A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated LiposarcomaEtrumadenantPhase 2Active, not recruitingMemorial Sloan Kettering Cancer CenterJun 2, 2023
      Study of Novel Treatment Combinations in Patients With Lung CancerEtrumadenantPhase 2Active, not recruitingGilead SciencesDec 1, 2022
      A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial CarcinomaEtrumadenantPhase 2Active, not recruitingM.D. Anderson Cancer CenterApr 20, 2022
      A Phase I-II Study to Test the Safety and Efficacy of PD1 (AB122) and Adenosine Receptor (AB928) Antagonists With Chemotherapy After Short-Course Radiation for Rectal Cancer.EtrumadenantPhase 2RecruitingWeill Medical College of Cornell UniversityAug 27, 2021
      Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung CancerEtrumadenantPhase 2Active, not recruitingWashington University School of MedicineMar 10, 2021
      Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical ProstatectomyEtrumadenantPhase 2RecruitingDavid OhJan 29, 2019

      Diseases most associated with it

      Open Targets association score, 0 to 1; all associations
      • Paroxysmal tachycardia0.59
      • Apnea0.57
      • Wolff-Parkinson-White syndrome0.56
      • Pain0.56
      • Airway obstruction0.55
      • Hepatic veno-occlusive disease0.53
      • Cardiovascular disorder0.49
      • Intermittent vascular claudication0.46

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL255, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. Gene name, function (UniProt P29275, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.